DE69334254D1 - Verfahren zur Zellkultivierung in einer Monoschicht - Google Patents

Verfahren zur Zellkultivierung in einer Monoschicht

Info

Publication number
DE69334254D1
DE69334254D1 DE69334254T DE69334254T DE69334254D1 DE 69334254 D1 DE69334254 D1 DE 69334254D1 DE 69334254 T DE69334254 T DE 69334254T DE 69334254 T DE69334254 T DE 69334254T DE 69334254 D1 DE69334254 D1 DE 69334254D1
Authority
DE
Germany
Prior art keywords
medium
monolayer
cells
culture
cell cultivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334254T
Other languages
English (en)
Inventor
Phillip J Provost
David L Krah
Paul A Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/893,295 external-priority patent/US5360736A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69334254D1 publication Critical patent/DE69334254D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25Varicella-zoster virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/36Lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69334254T 1992-06-04 1993-05-27 Verfahren zur Zellkultivierung in einer Monoschicht Expired - Lifetime DE69334254D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89403992A 1992-06-04 1992-06-04
US07/893,295 US5360736A (en) 1992-06-04 1992-06-04 Process for attenuated varicella zoster virus vaccine production

Publications (1)

Publication Number Publication Date
DE69334254D1 true DE69334254D1 (de) 2009-02-12

Family

ID=27129046

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69330850T Expired - Lifetime DE69330850T2 (de) 1992-06-04 1993-05-27 Verfahren zur Herstellung von Virusimpfstoff aus abgeschwächten Varicella Zoster Viren
DE69334254T Expired - Lifetime DE69334254D1 (de) 1992-06-04 1993-05-27 Verfahren zur Zellkultivierung in einer Monoschicht

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69330850T Expired - Lifetime DE69330850T2 (de) 1992-06-04 1993-05-27 Verfahren zur Herstellung von Virusimpfstoff aus abgeschwächten Varicella Zoster Viren

Country Status (28)

Country Link
US (1) US5607852A (de)
EP (2) EP1097988B1 (de)
JP (2) JP2599552B2 (de)
KR (1) KR100350169B1 (de)
CN (2) CN1069216C (de)
AT (2) ATE419332T1 (de)
AU (2) AU4392193A (de)
BG (1) BG62176B1 (de)
CA (1) CA2097019C (de)
CZ (2) CZ289574B6 (de)
DE (2) DE69330850T2 (de)
DK (2) DK0573107T3 (de)
ES (2) ES2161702T3 (de)
FI (1) FI117758B (de)
GR (1) GR3036812T3 (de)
HU (1) HU220080B (de)
MX (1) MX9303274A (de)
NO (1) NO314068B1 (de)
NZ (1) NZ253527A (de)
PT (2) PT1097988E (de)
RO (1) RO114906B1 (de)
RS (1) RS50330B (de)
RU (1) RU2126269C1 (de)
SK (1) SK279387B6 (de)
TW (1) TW349868B (de)
UA (1) UA27137C2 (de)
WO (1) WO1993024616A1 (de)
YU (1) YU49210B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029991A1 (en) * 1994-04-28 1995-11-09 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
AU4751697A (en) * 1996-10-10 1998-05-05 Douglas Danner Animal cell culture media comprising plant-derived nutrients
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
KR100378909B1 (ko) * 1998-03-18 2003-12-18 주식회사 엘지생명과학 사람세포주를이용한풍진백신의생산수율증대방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
EP1166797B1 (de) * 2000-01-31 2006-12-06 The Research Foundation for Microbial Diseases of Osaka University Verfahren zum kontrollieren der qualitäten eines abgeschwächten varicella phasen-impfstoffes
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
WO2008088410A2 (en) * 2006-10-17 2008-07-24 Medimmune, Llc Influencing viral lipid constituents
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
WO2010019572A1 (en) * 2008-08-11 2010-02-18 Sanofi Pasteur Biologics Co. Compositions and methods for the production of alpha-herpesviruses
CN101967466A (zh) 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
US20140147458A1 (en) * 2011-02-24 2014-05-29 Mogam Biotechnology Research Institute Novel varicella-zoster virus strains, and chicken pox and herpes zoster virus vaccine using same
WO2014062060A1 (en) * 2012-10-18 2014-04-24 Erasmus University Medical Center Rotterdam New method for producing high titer cell-free vzv vaccine virus
CN103074304B (zh) * 2013-01-28 2016-01-13 江苏健安生物科技有限公司 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法
EP3041505A4 (de) * 2013-09-05 2017-04-19 Merck Sharp & Dohme Corp. Immunisierungsverfahren mit einem varicella-zoster-virus-antigen
CN103740735B (zh) * 2013-12-31 2016-04-06 李越希 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用
DK3226894T3 (da) * 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660565A (en) * 1968-04-17 1972-05-02 Wistar Inst Rubella vaccine and method
US3555149A (en) * 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5341202B2 (de) * 1974-03-12 1978-11-01
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
JPS5251009A (en) * 1975-10-17 1977-04-23 Morinaga Milk Ind Co Ltd Method of producing drug for treating marrow leukemia
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
JPS5341202A (en) * 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4252792A (en) * 1979-09-21 1981-02-24 Douglas Industries, Inc. Injectable rabies vaccine composition and method for preparing same
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS624370A (ja) * 1985-07-01 1987-01-10 Sharp Corp 半導体素子
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
AU4312489A (en) * 1988-09-23 1990-04-18 Cetus Corporation Lipid microemulsions for culture media
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
DK0573107T3 (da) 2001-11-12
EP0573107B1 (de) 2001-10-04
KR100350169B1 (ko) 2004-05-20
NO944654L (no) 1995-02-03
ES2161702T3 (es) 2001-12-16
WO1993024616A1 (en) 1993-12-09
CN1082923A (zh) 1994-03-02
NO314068B1 (no) 2003-01-27
YU38893A (sh) 1996-02-19
AU4003693A (en) 1993-12-09
DE69330850D1 (de) 2001-11-08
AU673167B2 (en) 1996-10-31
HUT71863A (en) 1996-02-28
US5607852A (en) 1997-03-04
HU9403473D0 (en) 1995-02-28
ATE419332T1 (de) 2009-01-15
EP1097988B1 (de) 2008-12-31
RO114906B1 (ro) 1999-08-30
CZ289690B6 (cs) 2002-03-13
RS50330B (sr) 2009-11-10
AU4392193A (en) 1993-12-30
PT573107E (pt) 2002-02-28
JP2599552B2 (ja) 1997-04-09
SK148094A3 (en) 1995-07-11
GR3036812T3 (en) 2002-01-31
RU2126269C1 (ru) 1999-02-20
FI945697A (fi) 1995-01-26
CN1069216C (zh) 2001-08-08
CN1307902A (zh) 2001-08-15
BG99227A (bg) 1995-07-28
EP0573107A3 (de) 1995-04-26
YU7504A (sh) 2006-08-17
FI945697A0 (fi) 1994-12-02
HU220080B (hu) 2001-10-28
EP0573107A2 (de) 1993-12-08
UA27137C2 (uk) 2000-02-28
NZ253527A (en) 1996-09-25
SK279387B6 (sk) 1998-10-07
CZ289574B6 (cs) 2002-02-13
JP3156962B2 (ja) 2001-04-16
EP1097988A1 (de) 2001-05-09
ATE206311T1 (de) 2001-10-15
PT1097988E (pt) 2009-03-05
YU49210B (sh) 2004-09-03
CZ304594A3 (en) 1995-10-18
JPH06172215A (ja) 1994-06-21
BG62176B1 (bg) 1999-04-30
JPH09107958A (ja) 1997-04-28
CA2097019A1 (en) 1993-12-05
DK1097988T3 (da) 2009-05-04
FI117758B (fi) 2007-02-15
NO944654D0 (no) 1994-12-02
ES2317869T3 (es) 2009-05-01
TW349868B (en) 1999-01-11
CA2097019C (en) 2007-07-24
MX9303274A (es) 1994-01-31
DE69330850T2 (de) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE419332T1 (de) Verfahren zur zellkultivierung in einer monoschicht
DE69637656D1 (de) Methoden zur Züchtung von Tierzellen
ATE68211T1 (de) Verfahren zur kontinuierlichen herstellung von l- carnitin.
NO922887L (no) Fremgangsmaate for dannelse av cellemasse og/eller fermenteringsprodukter under sterile forhold samt anordning for utfoerelse av fremgangsmaaten
ATE67787T1 (de) Verfahren zur herstellung von proteinen mittels induzierbarer expressionssysteme in in-vivovermehrten, genetisch modifizierten eukaryotischen wirtszellen.
ATE220714T1 (de) Verfahren zur herstellung von proteinen
DE69821343D1 (de) Verfahren zur steigerung des wachstums von pflanzenzellkulturen
NO991211D0 (no) Apparat for dyrking av mikroorganismer
KR920012425A (ko) 동물세포 배양용 고농도 배지 및 배양공정
ATE76251T1 (de) Verfahren zur kultur von pflanzengewebe.
EP0987324A3 (de) Zellwachstumsbeschleunigungsmittel enthaltende Polyphosphorsäure und Zellwachstumsmethode
EP0276154A3 (de) Methode und Apparat zur Züchtung von Zellen
EP0263659A3 (de) Gewebekulturmedien die L-Karnitin enthalten
JPS5668395A (en) Production of d(-)-beta-hydroxyisobutyric acid
RU93048367A (ru) Способ получения шиконина-5,8-дигидрокси-3-/1-гидрокси-4-метил-3-пентил/-1,4-нафтохинона
RU93045458A (ru) Способ культивирования галофильных бактерий

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1097988

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1097988

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213